# Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

> **NCT06611657** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (actual)

## Conditions studied

- Whole Brain Radiotherapy

## Interventions

- **DRUG:** Antirotinib hydrochloride

## Key facts

- **NCT ID:** NCT06611657
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-20
- **Primary completion:** 2024-06-10
- **Final completion:** 2025-07-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611657, "Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06611657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*